Actively Recruiting
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Led by Canadian Cancer Trials Group · Updated on 2026-04-16
236
Participants Needed
14
Research Sites
273 weeks
Total Duration
On this page
Sponsors
C
Canadian Cancer Trials Group
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach? This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.
CONDITIONS
Official Title
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologic diagnosis of prostate adenocarcinoma without neuroendocrine or small cell carcinoma
- Prior treatment with androgen receptor pathway inhibitors such as abiraterone, enzalutamide, apalutamide, or darolutamide
- Recovery to grade 1 or less from prior treatment toxicities except chemotherapy-induced hair loss and grade 2 peripheral neuropathy
- Adequate washout periods from prior therapies according to specified timelines
- Major surgery completed at least 28 days before enrollment with wound healing
- Prior external beam radiation completed at least 7 days before enrollment
- Radiologic evidence of metastatic disease within 28 days before randomization
- Disease progression after androgen receptor pathway inhibitor therapy shown by PSA or radiographic criteria
- Medical or surgical castration with testosterone levels below 50 ng/dL or 1.7 mmol/L
- Presence of qualifying DNA damage response gene alterations of clinical significance, excluding monoallelic deletions
- Age 18 years or older
- ECOG Performance Status of 2 or less
- Adequate organ and marrow function within 14 days before enrollment
- Life expectancy longer than 12 weeks
- Agreement to use medically accepted contraception during and for 6 months after treatment if of childbearing potential
- Ability to complete quality of life questionnaires in English or French
- Signed informed consent and availability for treatment and follow-up
- Treatment to begin within 2 working days after enrollment
You will not qualify if you...
- Prior platinum or taxane chemotherapy for prostate cancer, except limited docetaxel after curative treatment for localized disease with at least 12 months since last treatment
- Active anticancer systemic therapy or investigational agents within 14 days of randomization
- Uncontrolled illnesses including active infection, severe heart failure, unstable angina, arrhythmias, uncontrolled hypertension, or psychiatric/social issues limiting compliance
- Myelodysplastic syndrome or acute myeloid leukemia
- Malignancy within past 2 years with high risk of recurrence except certain skin and bladder cancers
- Symptomatic brain metastases, though stable treated asymptomatic metastases are allowed
- Symptomatic or impending spinal cord compression unless treated and stable
- Conditions that pose significant risk or interfere with study participation as judged by investigator
- Live attenuated vaccine within 30 days prior to randomization
- For HIV patients, undetectable viral load on therapy within 6 months
- For hepatitis B or C, viral load control or cure with treatment
- Inability to obtain provincial reimbursement for study drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
3
BCCA - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
4
William Osler Health System
Brampton, Ontario, Canada, L6R 3J7
Actively Recruiting
5
Waterloo Regional Health Network (WRHN)
Kitchener, Ontario, Canada, N2G 1G3
Actively Recruiting
6
London Health Sciences Centre Research Inc.
London, Ontario, Canada, N6A 5W9
Actively Recruiting
7
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
8
Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
9
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
10
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
11
The Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
12
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
Québec, Quebec, Canada, G1J 1Z4
Actively Recruiting
13
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
Actively Recruiting
14
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada, S7N 4H4
Actively Recruiting
Research Team
M
Mariam Jafri
CONTACT
W
Wendy Parulekar
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here